Liu W, Hu H, Li C, Shi Q, Liu C, Liu A
J Headache Pain. 2024; 25(1):206.
PMID: 39587512
PMC: 11587596.
DOI: 10.1186/s10194-024-01913-0.
Rushendran R, Singh A, Singh S, Chitra V, Ilango K
Front Neurol. 2024; 15:1307319.
PMID: 38836002
PMC: 11148868.
DOI: 10.3389/fneur.2024.1307319.
McConnachie L, Goadsby P, Vann R, Ray S, Shrewsbury S, Aurora S
Front Neurol. 2023; 14:1282846.
PMID: 38073648
PMC: 10703426.
DOI: 10.3389/fneur.2023.1282846.
Mitsikostas D, Waeber C, Sanchez-Del-Rio M, Raffaelli B, Ashina H, Brink A
Nat Rev Neurol. 2023; 19(8):489-505.
PMID: 37438431
DOI: 10.1038/s41582-023-00842-x.
Ogunlaja O, Goadsby P
eNeurologicalSci. 2023; 29:100420.
PMID: 36636337
PMC: 9830470.
DOI: 10.1016/j.ensci.2022.100420.
Psychosomatic symptoms related to exacerbation of fatigue in patients with medically unexplained symptoms.
Hashimoto K, Takeuchi T, Murasaki M, Hiiragi M, Koyama A, Nakamura Y
J Gen Fam Med. 2023; 24(1):24-29.
PMID: 36605910
PMC: 9808159.
DOI: 10.1002/jgf2.582.
Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
Yu T, He L, Yang X, Zhou J, Luo G, Wang H
Neurol Ther. 2022; 11(3):1269-1283.
PMID: 35713760
PMC: 9338201.
DOI: 10.1007/s40120-022-00369-1.
Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis.
Krege J, Lipton R, Baygani S, Komori M, Ryan S, Vincent M
Pain Ther. 2022; 11(2):701-712.
PMID: 35471625
PMC: 9098729.
DOI: 10.1007/s40122-022-00388-8.
Role of Neuroinflammation and Blood-Brain Barrier Permutability on Migraine.
Yamanaka G, Suzuki S, Morishita N, Takeshita M, Kanou K, Takamatsu T
Int J Mol Sci. 2021; 22(16).
PMID: 34445635
PMC: 8396312.
DOI: 10.3390/ijms22168929.
Migraine and Sleep-An Unexplained Association?.
Waliszewska-Prosol M, Nowakowska-Kotas M, Chojdak-Lukasiewicz J, Budrewicz S
Int J Mol Sci. 2021; 22(11).
PMID: 34073933
PMC: 8197397.
DOI: 10.3390/ijms22115539.
Inflammation induces developmentally regulated sumatriptan inhibition of spinal synaptic transmission.
Winters B, Jeong H, Vaughan C
Br J Pharmacol. 2020; 177(16):3730-3743.
PMID: 32352556
PMC: 7393196.
DOI: 10.1111/bph.15089.
Application of Factorial and Doehlert Designs for the Optimization of the Simultaneous Separation and Determination of Antimigraine Drugs in Pharmaceutical Formulations by RP-HPLC-UV.
Jebali S, Belgacem C, Louhaichi M, Bahri S, Latrous El Atarche L
Int J Anal Chem. 2019; 2019:9685750.
PMID: 31511775
PMC: 6714324.
DOI: 10.1155/2019/9685750.
Primary headache disorders: Five new things.
Goadsby P
Neurol Clin Pract. 2019; 9(3):233-240.
PMID: 31341711
PMC: 6615655.
DOI: 10.1212/CPJ.0000000000000654.
Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
Krege J, Rizzoli P, Liffick E, Doty E, Dowsett S, Wang J
Cephalalgia. 2019; 39(8):957-966.
PMID: 31166697
PMC: 6787764.
DOI: 10.1177/0333102419855080.
Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding.
Deen M, Hougaard A, Hansen H, Schain M, Dyssegaard A, Knudsen G
JAMA Neurol. 2019; 76(7):834-840.
PMID: 31135819
PMC: 6547094.
DOI: 10.1001/jamaneurol.2019.0755.
Therapeutic novelties in migraine: new drugs, new hope?.
Do T, Guo S, Ashina M
J Headache Pain. 2019; 20(1):37.
PMID: 30995909
PMC: 6734360.
DOI: 10.1186/s10194-019-0974-3.
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
Kuca B, Silberstein S, Wietecha L, Berg P, Dozier G, Lipton R
Neurology. 2018; 91(24):e2222-e2232.
PMID: 30446595
PMC: 6329326.
DOI: 10.1212/WNL.0000000000006641.
Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice.
Oswald J, Schuster N
J Pain Res. 2018; 11:2221-2227.
PMID: 30323656
PMC: 6181111.
DOI: 10.2147/JPR.S152216.
Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.
Cottier K, Galloway E, Calabrese E, Tome M, Liktor-Busa E, Kim J
eNeuro. 2018; 5(4).
PMID: 30073201
PMC: 6071204.
DOI: 10.1523/ENEURO.0116-18.2018.
Migraine Therapy: Current Approaches and New Horizons.
Goadsby P, Holland P
Neurotherapeutics. 2018; 15(2):271-273.
PMID: 29667112
PMC: 5935654.
DOI: 10.1007/s13311-018-0626-3.